Literature DB >> 23529731

In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.

Ellie J C Goldstein1, Diane M Citron, Kerin L Tyrrell, C Vreni Merriam.   

Abstract

Biapenem is a carbapenem being developed in combination with RPX7009, a new inhibitor of serine β-lactamases. Biapenem was tested alone and in combination with fixed concentrations of RPX7009 by agar dilution against 377 recent isolates of anaerobes. A separate panel of 27 isolates of Bacteroides spp. with decreased susceptibility or resistance to imipenem was also tested. Comparator drugs included meropenem, piperacillin-tazobactam, ampicillin-sulbactam, cefoxitin, ceftazidime, metronidazole, clindamycin, and tigecycline plus imipenem, doripenem, and ertapenem for the 27 selected strains. For recent consecutive strains of Bacteroides species, the MIC(90) for biapenem-RPX7009 was 1 μg/ml, with a MIC(90) of 4 μg/ml for meropenem. Other Bacteroides fragilis group species showed a MIC90 of 0.5 μg/ml for both agents. The MIC(90)s for biapenem-RPX7009 were 0.25 μg/ml for Prevotella spp., 0.125 μg/ml for Fusobacterium nucleatum and Fusobacterium necrophorum, 2 μg/ml for Fusobacterium mortiferum, 0.5 μg/ml for Fusobacterium varium, ≤ 0.5 μg/ml for Gram-positive cocci and rods, and 0.03 to 8 μg/ml for clostridia. Against 5 B. fragilis strains harboring a known metallo-beta-lactamase, biapenem-RPX7009 MICs were comparable to those of other carbapenems (≥ 32 μg/ml). Against Bacteroides strains with an imipenem MIC of 2 μg/ml, biapenem-RPX7009 had MICs of 0.5 to 2 μg/ml, with MICs of 0.5 to 32 μg/ml for meropenem, doripenem, and ertapenem. For strains with an imipenem MIC of 4 μg/ml, the MICs for biapenem-RPX7009 were 4 to 16 μg/ml, with MICs of 8 to >32 μg/ml for meropenem, doripenem, and ertapenem. The inhibitor RPX7009 had no antimicrobial activity when tested alone, and it showed little or no potentiation of biapenem versus anaerobes. Biapenem-RPX7009 showed activity comparable to that of imipenem and was superior to meropenem, doripenem, and ertapenem against imipenem-nonsusceptible Bacteroides spp.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23529731      PMCID: PMC3716157          DOI: 10.1128/AAC.02418-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  In vitro activity of L-627 against anaerobic bacteria.

Authors:  C E Nord; A Lindmark; I Persson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

2.  L-627, a novel carbapenem: in-vitro activity against anaerobes.

Authors:  J A García-Rodríguez; J E García-Sánchez; I Trujillano-Martín; E García-Sánchez; I García-García; J Fresnadillo-Martínez
Journal:  J Antimicrob Chemother       Date:  1994-01       Impact factor: 5.790

3.  The in-vitro activity of L-627 against anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; S M Finegold
Journal:  J Antimicrob Chemother       Date:  1994-03       Impact factor: 5.790

Review 4.  Biapenem.

Authors:  Caroline M Perry; Tim Ibbotson
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes.

Authors:  K E Aldridge; N Morice; D D Schiro
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

6.  In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria.

Authors:  G J Malanoski; L Collins; C Wennersten; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

7.  Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.

Authors:  P C Appelbaum; S K Spangler; M R Jacobs
Journal:  J Antimicrob Chemother       Date:  1993-08       Impact factor: 5.790

8.  Comparative in vitro activity of biapenem, a new carbapenem antibiotic.

Authors:  A M Clarke; S J Zemcov
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

9.  Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by beta-lactamases.

Authors:  Y Yang; N Bhachech; K Bush
Journal:  J Antimicrob Chemother       Date:  1995-01       Impact factor: 5.790

10.  In vitro activity of L-627, a new carbapenem.

Authors:  C R Catchpole; R Wise; D Thornber; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

View more
  19 in total

Review 1.  New promising β-lactamase inhibitors for clinical use.

Authors:  I Olsen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-04-12       Impact factor: 3.267

2.  Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens.

Authors:  Erin E Gill; Octavio L Franco; Robert E W Hancock
Journal:  Chem Biol Drug Des       Date:  2015-01       Impact factor: 2.817

Review 3.  Fragment-based inhibitor discovery against β-lactamase.

Authors:  Derek A Nichols; Adam R Renslo; Yu Chen
Journal:  Future Med Chem       Date:  2014-03       Impact factor: 3.808

4.  Eggerthella lenta bacteremia complicated by spondylodiscitis, psoas abscess, and meningitis.

Authors:  B J Gardiner; T M Korman; R K Junckerstorff
Journal:  J Clin Microbiol       Date:  2014-01-15       Impact factor: 5.948

5.  Recent Advances in the Rational Design and Optimization of Antibacterial Agents.

Authors:  Jesse A Jones; Kristopher G Virga; Giuseppe Gumina; Kirk E Hevener
Journal:  Medchemcomm       Date:  2016-07-07       Impact factor: 3.597

Review 6.  Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

Authors:  George G Zhanel; Courtney K Lawrence; Heather Adam; Frank Schweizer; Sheryl Zelenitsky; Michael Zhanel; Philippe R S Lagacé-Wiens; Andrew Walkty; Andrew Denisuik; Alyssa Golden; Alfred S Gin; Daryl J Hoban; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2018-01       Impact factor: 9.546

7.  Clinical and microbiological characteristics of Eggerthella lenta bacteremia.

Authors:  B J Gardiner; A Y Tai; D Kotsanas; M J Francis; S A Roberts; S A Ballard; R K Junckerstorff; T M Korman
Journal:  J Clin Microbiol       Date:  2014-12-17       Impact factor: 5.948

Review 8.  New β-Lactamase Inhibitors in the Clinic.

Authors:  Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2016-06       Impact factor: 5.982

Review 9.  Diversity and Proliferation of Metallo-β-Lactamases: a Clarion Call for Clinically Effective Metallo-β-Lactamase Inhibitors.

Authors:  Anou M Somboro; John Osei Sekyere; Daniel G Amoako; Sabiha Y Essack; Linda A Bester
Journal:  Appl Environ Microbiol       Date:  2018-08-31       Impact factor: 4.792

10.  Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria.

Authors:  Twisha S Patel; Jason M Pogue; John P Mills; Keith S Kaye
Journal:  Future Microbiol       Date:  2018-04-25       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.